Volpara Showcases Intelligent Breast Cancer Screening Platform at AHRA

WELLINGTON, New Zealand, Aug. 10, 2020 /PRNewswire/ -- Volpara Solutions will spotlight the Volpara(®)Platform(TM), a comprehensive suite of artificial intelligence and software tools that improve breast cancer detection, at the Association for Medical Imaging Management (AHRA) 2020 virtual conference on August 11-13.

The VolparaPlatform clinical decision support tools enable radiologists to make informed and timely decisions about a patient's need for supplemental imaging and/or genetic testing as part of personalized breast care. Volpara(®)Scorecard+(TM) software provides three key patient risk insights, including:

    --  Breast density. Volpara(®)Density((TM)) software uses artificial
        intelligence (AI), physics and imaging data to provide radiologists with
        an automated, objective, volumetric breast density assessment.
    --  Short-term risk. Transpara(®) software by ScreenPoint Medical uses AI
        to automatically assign each screening mammogram a score from 1 to 10.
        Exams with a high score are more likely to contain breast cancer.
    --  Lifetime risk. Volpara(®)Risk(TM) software captures patient information
        through a simple, easy-to-use interface. VolparaRisk uses that
        information, along with the VolparaDensity score, to calculate a woman's
        lifetime risk of developing breast cancer using the Tyrer-Cuzick Breast
        Cancer Risk model (TC8).

"Our vision is to offer each woman a personalized screening regimen for the earliest detection of breast cancer based on her breast density, risk factors and hereditary testing. Using Volpara's AI-driven, automated breast density to implement a risk-stratified screening program, we have seen tremendous compliance to screening schedules," reports Leigh Loughran, Operations Manager Medical Imaging at Rome Memorial Hospital, Rome, New York.

In addition to Scorecard, VolparaPlatform supports clinics with continuous image quality improvement and workflow productivity tools. These include:

    --  Volpara(®)Live!(TM) software analyzes ideal patient positioning,
        radiation dose and compression in real time to provide actionable
        feedback. If needed, the technologist can use the recommendations to
        retake the image immediately, to ensure image quality and to reduce call

    --  Volpara(®)Enterprise(TM) software provides a full view of productivity
        at the technologist, room, department, and enterprise level. This
        includes tracking the number of studies per day, time of day, and study
        duration per room. The software also calculates and monitors the dose
        delivered to patients to ensure that the equipment is performing safely.
    --  Aspen(®) Breast mammography reporting and patient tracking software
        streamlines workflow by customizing reports and patient letters to
        include the radiologist's recommendations based on imaging studies and
        the results of breast cancer risk models including TC8.  Aspen Breast
        now provides the option of generating medical necessity letters for
        insurance pre-authorizations for supplemental screening and testing

"Healthcare is always going to be a human-centered business. Our goal is to mesh the best of technology with the best of human." said Dr. Lloyd McCann, CEO, Mercy Radiology, Auckland, New Zealand. "We want to enable our providers with the best technology so they can spend more time connecting with patients."

About Volpara Solutions
Volpara's advanced technology platform combines with the healthcare provider's expertise to provide a high-quality, optimized, and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, our platform collects and analyzes information to better understand a patient's breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. These capabilities are being extended to lung cancer screening. The VolparaPlatform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking, and validated by a volume of peer-reviewed publications unrivaled in the breast screening industry. For more information, visit http://www.volparasolutions.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/volpara-showcases-intelligent-breast-cancer-screening-platform-at-ahra-301108910.html

SOURCE Volpara Solutions